Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort

Table 3 Structural disease progression in patients with early RA who received DMARDs and the entire ESPOIR cohort.

	SD-treated patients	All ESPOIR patients
All patients	(number = 370)	(number = 736^a)
- ΔvSHS total	1.6 ± 5.5 (0)	0.96 ± 4.4 (0)
- ΔvSHS erosion	1.5 ± 4.7 (0)	0.96 ± 3.8 (0)
- ΔvSHS narrowing	0.2 ± 1.8 (0)	0.01 ± 1.81 (0)
Patients with structural progression ^b	(number = 126, 34.1%)	(number = 187, 25.4%)
- ΔvSHS total	5.4 ± 7.0 [54]	5.0 ± 6.3 [54]
- ΔvSHS ≥ 5 points (RRP)	41 (11.1%)	58 (7.9%)

Data are mean ± SD (median) or number (%).^aX-ray data were available for only 736 patients; ^bStructural progression was defined as ΔvSHS ≥ 1 point (that is, the smallest detectable difference). DMARD, disease-modifying anti-rheumatic drugs; RRP, rapid radiographic progression; SD, synthetic DMARD; ΔvSHS, change in van der Heijde-modified Sharp score.

ISSN: 1478-6362